STAT+: GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug

GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions.
Click here to view original post

Advertisement — Advertise with Biotech Networks